Tag: cancer treatmentSort
Cellceutix Announces Kevetrin Non-Genotoxic as Cancer Therapy
Cellceutix Corporation has made two significant announcements this week pertaining to Kevetrin, their flagship compound for the treatment of drug-resistant cancers. Not only has pre-clinical data produced very promising data as a therapy for breast, lung and colon cancer, the recent data as clinical trials approach this year can only be considered big news for the cancer industry.
Source CRWESelect : CBLI, PWRM.OB, PNCL, ORFG.PK, INXI, - Cleveland BioLabs, Power3 Medical Products, Pinnacle Airlines Corp.
Cleveland BioLabs, Inc. (NASDAQ:CBLI) previously reported that CBLB502, a drug under development to treat exposure to radiation, has been granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster.
CRIS, CRWE.OB, HZO, LB - PennyToBuck.com Morning Stock Alert - Curis Inc, Crown Equity Holdings, MarineMax Inc, LaBarge Inc
PROT, ISR, ISRL, ISTA - Consumers Using Company Products by Stock-PR.com
Proteonomix, Inc. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon human cells and their derivatives, announced further developments with Proteonomix's Joint Venture Company, XGEN Medical LLC ("XGen") towards implementing operations in the United Arab Emirates (U.A.E.).
Businesses Are Doing Consumers Right - ARIA, CRWE, ARBA, ARKR by Stock-PR.com
PWRM, MYRX, MYGN, GPRO - Company News And Updates From DrStockPick.com .
PROT.OB, MYRX, XOMAD BioMedical Market Update from PennyOtcStock.com
Proteonomix, Inc., (OTCBB:PROT.OB) a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, is pleased to provide an update on the Company's successful international approach to commercializing its proprietary and patent pending stem cell technologies.